Aviado · Research
Longevity Daily
Monday, September 28, 2026
Listen
Today's Brief
A landmark BMJ meta-analysis finds calcium and vitamin D supplements offer little to no protection against fractures — a finding that affects millions who take them for exactly that reason. Creatine continues its winning streak with new evidence of muscle gains even without exercise, and Aviado's spirulina deep-dive reveals a surprising nuance: it only works if your liver enzymes are already elevated. Cellular reprogramming crossed a historic threshold this summer with its first human trial. Rounding out today's issue, Al Jazeera asks whether the longevity industry's $3.74bn investment surge is outrunning the science.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Mediterranean Diet May Shield the Aging Brain — Through the Gut
A narrative review published in News-Medical proposes that the Mediterranean diet's brain benefits may flow through gut microbiome remodeling, reduced inflammatory signaling, and stronger intestinal and blood-brain barrier function — with potential relevance to Alzheimer's and Parkinson's disease pathways. The proposed chain runs from dietary polyphenols and fiber to microbial metabolites that dampen neuroinflammation. Key caveat: the review is narrative, not a meta-analysis, and direct human evidence that microbiome changes actually mediate brain protection remains limited — this is a compelling mechanistic hypothesis, not yet a confirmed causal pathway.
Read more →Supplements & Compounds
The Fracture-Prevention Myth: Major BMJ Analysis Finds Calcium and Vitamin D Supplements Don't Deliver
A systematic review and meta-analysis published in The BMJ on September 27, 2026, found that calcium and vitamin D supplements provide little to no meaningful protection against bone fractures or falls in older adults — directly challenging decades of standard medical advice. This is one of the most widely taken supplement combinations in medicine, prescribed and purchased by tens of millions specifically for bone protection. The review is large-scale and peer-reviewed, making it difficult to dismiss: effect sizes were essentially flat regardless of dose or formulation. If preventing fractures is your primary reason for taking these, this is the moment to revisit that conversation with your doctor and explore evidence-backed alternatives like weight-bearing exercise.
Read more →Creatine Builds Muscle and Strength Even Without Exercise, New Research Confirms
Texas A&M University trials confirm that creatine supplementation improves muscle mass, strength, and cognitive and metabolic markers even in sedentary older adults — no gym required. This matters most for people who face barriers to exercise due to illness, injury, or mobility challenges, offering a meaningful floor of benefit. That said, the strongest creatine evidence still pairs it with resistance training — these findings suggest a minimum effective dose of benefit, not a full substitute for movement.
Read more →Spirulina's Effect on Liver Enzymes Is Fast and Measurable — But Only If Your Baseline Is Elevated
Most people taking spirulina expect broad liver benefits, but Aviado's analysis of available research reveals it barely moves the needle in people with normal liver enzyme levels. The real value is highly targeted: if your ALT or AST is elevated from fatty liver or metabolic dysfunction, spirulina can produce measurable drops within two weeks at 2–3 grams daily. The protocol is clear — get a liver panel before you supplement; otherwise you may be spending money on a compound that does nothing for you.
Read the full Aviado analysis →Research & Papers
Cellular Reprogramming Enters Human Trials — A Landmark Milestone for Age Reversal Science
In June 2026, a glaucoma patient received the first-ever injection of a genetic cocktail designed to reprogram aging cells, marking a watershed moment in longevity science's transition from mice to humans. The trial is rooted in Yamanaka factor-based epigenetic reprogramming, which has shown dramatic rejuvenation effects in animal studies over the past decade. Early safety and efficacy data are not yet published, but the milestone itself signals that age reversal is no longer a theoretical framework — it is entering clinical medicine.
Read more →Phase II Data Reveals How Low-Dose Rapamycin May Work in ME/CFS — With Longevity Implications
A new paper in the Journal of Translational Medicine (Gile, Roy et al., 2026) delivers some of the most mechanistically detailed human evidence yet for low-dose rapamycin as a treatment for ME/CFS and Long COVID. The phase II data show measurable changes in immune and metabolic signaling pathways consistent with rapamycin's known mTOR-inhibiting action. For longevity watchers, the overlap is hard to ignore: the mechanisms proposed here are largely the same ones underlying rapamycin's anti-aging effects, making this a real-world signal in a living human population.
Read more →Senolytics vs. Senomorphics: The Emerging Antiaging Toolkit That Could Redefine How We Treat Old Cells
A Dermatology Times review maps the emerging class of senotherapeutics — drugs that either destroy senescent cells outright (senolytics) or suppress their harmful secretory output (senomorphics). Notably, chronic low-dose metformin was shown to reduce expression of senescence-associated β-galactosidase in human fibroblast cultures, adding anti-senescence to its growing list of potential longevity benefits. This is cell culture data, not a clinical trial — but the convergence of metformin's metabolic, anti-inflammatory, and now senolytic properties continues to build a compelling case.
Read more →Lifestyle & Nutrition
Dan Buettner: Dog Ownership Is One of the Most Underrated Longevity Habits
Blue Zones founder Dan Buettner highlights a growing body of scientific evidence linking dog ownership to a significantly reduced risk of early death, particularly from cardiovascular disease. The benefits appear to work through multiple overlapping pathways: more daily movement, reduced loneliness, and reinforcement of the kind of routine and social purpose that characterize the world's longest-lived communities. For people already optimizing their health, a four-legged companion may be the one habit that quietly reinforces everything else.
Read more →GLP-1s in Perimenopause: Beyond Weight Loss, a Potential Longevity Window
Forward-thinking clinicians are exploring GLP-1 receptor agonists like semaglutide for perimenopausal women not just for weight management but for their cardiovascular, anti-inflammatory, and neuroinflammatory effects — prompting some researchers to ask whether they may be the first true longevity drugs. Landmark trials including LEADER, SUSTAIN-6, and SELECT showed major reductions in heart attack, stroke, and cardiovascular death, with only about a third of the cardiovascular benefit explained by weight loss alone. If you're a perimenopausal woman considering GLP-1s, the conversation with your doctor warrants going well beyond the scale.
Read more →Industry & Policy
The Longevity Boom Is Getting Ahead of the Science, Al Jazeera Warns
Longevity biotech companies raised approximately $3.74 billion in Q1 2026 alone — a pace that Al Jazeera's opinion writers argue is dramatically outrunning the evidence base. Most interventions have only been validated in animal models, clinical translation remains slow, and the gap between investor enthusiasm and peer-reviewed proof is widening. For health-conscious readers: the same skepticism you apply to supplement marketing applies to billion-dollar longevity startups too.
Read more →